SHR6390
Sponsors
Jiangsu HengRui Medicine Co., Ltd., Peking University, Harbin Medical University, Jinming Yu, Ruijin Hospital
Conditions
Advanced Breast CancerBreast CancerCRCER-positive Breast CancerGastric CancerHCCHER2-positive Breast CancerHealthy Participants
Phase 1
A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients
NCT02671513
Start: 2016-01-31End: 2017-04-30Target: 30Updated: 2016-04-12
A Study of SHR6390 in Advanced Solid Tumor Patients
CompletedNCT02684266
Start: 2016-03-03End: 2019-06-28Updated: 2022-07-11
Study to Evaluate SHR6390 Combined With Pyrotinib in Patients With HER2 Positive Gastric Cancer
NCT03480256
Start: 2018-07-27End: 2020-08-31Target: 40Updated: 2019-03-14
A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
CompletedNCT03481998
Start: 2018-03-22End: 2022-07-30Updated: 2023-11-21
A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC
NCT03601598
Start: 2018-07-30End: 2020-07-30Target: 41Updated: 2018-07-26
A Trial of SHR6390 in Healthy Caucasian Volunteers
CompletedNCT04301804
Start: 2020-03-12End: 2020-09-28Updated: 2022-07-14
An Investigational Study of SHR6390 in Participants With Mild to Moderate Liver Impairment and Healthy Participants
NCT04631575
Start: 2020-12-31End: 2021-03-31Target: 24Updated: 2020-11-17
Study to Investigate Relative Bioavailability of Different Formulations of SHR6390 in Healthy Subjects
CompletedNCT04667156
Start: 2020-12-13End: 2021-01-29Updated: 2021-10-12
Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer
TerminatedNCT05176080
Start: 2021-12-08End: 2024-07-03Updated: 2024-12-17
Study of SHR6390 in Renal Insufficiency and Healthy Subjects
NCT05515289
Start: 2022-12-18End: 2023-09-28Target: 30Updated: 2023-03-10
Phase 2
A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer
NCT04095390
Start: 2019-09-30End: 2022-08-30Target: 60Updated: 2019-09-19
A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.
NCT04236310
Start: 2020-01-15End: 2022-12-31Target: 37Updated: 2020-01-22
Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer
NCT04293276
Start: 2020-04-01End: 2023-05-31Target: 41Updated: 2023-05-06
Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer
NCT04355858
Start: 2020-05-01End: 2025-04-01Target: 319Updated: 2022-07-26
A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.
NCT04733417
Start: 2021-05-26End: 2023-09-30Target: 35Updated: 2023-04-13
SHR6390 Plus Nab-paclitaxel and Gemcitabine in Advanced/Metastatic Pancreatic Cancer
NCT05185869
Start: 2022-01-31End: 2025-10-31Target: 58Updated: 2022-01-11
Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02
RecruitingNCT05205200
Start: 2022-06-06End: 2026-08-01Target: 338Updated: 2024-02-08
Phase 3
A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
NCT03927456
Start: 2019-06-13End: 2022-12-30Target: 357Updated: 2021-06-03
Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative
Active, not recruitingNCT04842617
Start: 2021-04-30End: 2031-10-31Updated: 2024-08-01